Approval Package for:

APPLICATION NUMBER: 200153Orig1s000

Trade Name: Liptruzet Tablets 10 mg/10 mg, 10 mg/20 mg, 10 mg/40 mg, 10 mg/80 mg

Generic Name: Ezetimibe and Atorvastatin

Sponsor: Merck Sharp & Dohme Corp.
(US Agent for MSD International GmbH)

Approval Date: 05/03/2013

Indications:
Reduce elevated total-C, LDL-C, Apo B, TG, and non-HDL-C, and to increase HDL-C in patients with primary (heterozygous familial and non-familial) hyperlipidemia or mixed hyperlipidemia.

Reduce elevated total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH), as an adjunct to other lipid-lowering treatments.
### CENTRAL FOR DRUG EVALUATION AND RESEARCH

**APPLICATION NUMBER:**
200153Orig1s000

### CONTENTS

<table>
<thead>
<tr>
<th>Reviews / Information Included in this NDA Review.</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Approval Letter</td>
<td>X</td>
</tr>
<tr>
<td>Other Action Letters</td>
<td>X</td>
</tr>
<tr>
<td>Labeling</td>
<td>X</td>
</tr>
<tr>
<td>REMS</td>
<td></td>
</tr>
<tr>
<td>Summary Review</td>
<td>X</td>
</tr>
<tr>
<td>Officer/Employee List</td>
<td>X</td>
</tr>
<tr>
<td>Office Director Memo</td>
<td></td>
</tr>
<tr>
<td>Cross Discipline Team Leader Review</td>
<td></td>
</tr>
<tr>
<td>Medical Review(s)</td>
<td>X</td>
</tr>
<tr>
<td>Chemistry Review(s)</td>
<td>X</td>
</tr>
<tr>
<td>Environmental Assessment</td>
<td></td>
</tr>
<tr>
<td>Pharmacology Review(s)</td>
<td>X</td>
</tr>
<tr>
<td>Statistical Review(s)</td>
<td>X</td>
</tr>
<tr>
<td>Microbiology Review(s)</td>
<td></td>
</tr>
<tr>
<td>Clinical Pharmacology/Biopharmaceutics Review(s)</td>
<td>X</td>
</tr>
<tr>
<td>Other Reviews</td>
<td>X</td>
</tr>
<tr>
<td>Risk Assessment and Risk Mitigation Review(s)</td>
<td></td>
</tr>
<tr>
<td>Proprietary Name Review(s)</td>
<td>X</td>
</tr>
<tr>
<td>Administrative/Correspondence Document(s)</td>
<td>X</td>
</tr>
</tbody>
</table>
APPLICATION NUMBER:
200153Orig1s000

APPROVAL LETTER
Dear Dr. Kohler:

Please refer to your New Drug Application (NDA) dated and received September 2, 2009, submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act for Liptruzet (ezetimibe and atorvastatin) Tablets, 10 mg/10 mg, 10 mg/20 mg, 10 mg/40 mg, and 10 mg/80 mg.

We acknowledge receipt of your amendments dated September 2 (2), 11, October 27, November 12 and 13, 2009, and April 13, 28 and 29, June 23, July 7, 18, 22, 28, and 29, August 10, 22, and 26, September 12, 14, and 22 (2), October 11, 17, and 31, November 11 and 14, 2011, and March 20, April 16, May 3, October 31, November 5, and December 14, 2012, February 6, 7, and 25, March 6, and April 2, 2013. We also acknowledge receipt of your email dated May 1, 2013, stating your agreement to the labeling revisions (Patient Information) that we communicated to you by email on May 1, 2013. Lastly, we acknowledge receipt of your email dated May 2, 2013, stating your agreement to the labeling revisions (Package Insert) that we communicated to you on May 2, 2013.


This new drug application provides for the use of Liptruzet tablets as adjunctive therapy to diet to:

- reduce elevated total-C, LDL-C, Apo B, TG, and non-HDL-C, and to increase HDL-C in patients with primary (heterozygous familial and non-familial) hyperlipidemia or mixed hyperlipidemia.
- reduce elevated total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH), as an adjunct to other lipid-lowering treatments.

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling text.
**WAIVER OF HIGHLIGHTS SECTION**

We are waiving the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of prescribing information. This waiver applies to all future supplements containing revised labeling unless we notify you otherwise.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at [http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm](http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm). Content of labeling must be identical to the enclosed labeling (text for the package insert, text for the patient package insert). Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*, available at [http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf](http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf).

The SPL will be accessible via publicly available labeling repositories.

**CARTON AND IMMEDIATE-CONTAINER LABELS**

Submit final printed carton and immediate-container labels that are identical to the enclosed carton and immediate-container labels (submitted on April 2, 2013) as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (June 2008)*. Alternatively, you may submit 12 paper copies, with 6 of the copies individually mounted on heavy-weight paper or similar material. For administrative purposes, designate this submission “Final Printed Carton and Container Labels for approved NDA 200153.” Approval of this submission by FDA is not required before the labeling is used.

Marketing the product(s) with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

**REQUIRED PEDIATRIC ASSESSMENTS**

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

We are waiving the pediatric study requirement for this application because for ages 0 through 9 years necessary studies are impossible or highly impracticable; for pediatric patients aged 10 through 17 this product does not represent a meaningful therapeutic benefit over existing
therapies for pediatric patients and is not likely to be used in a substantial number of pediatric patients.

**PROMOTIONAL MATERIALS**

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit, in triplicate, a cover letter requesting advisory comments, the proposed materials in draft or mock-up form with annotated references, and the package insert to:

Food and Drug Administration  
Center for Drug Evaluation and Research  
Office of Prescription Drug Promotion  
5901-B Ammendale Road  
Beltsville, MD 20705-1266

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the package insert, at the time of initial dissemination or publication, accompanied by a Form FDA 2253. For instruction on completing the Form FDA 2253, see page 2 of the Form. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see [http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm](http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm).

**METHODS VALIDATION**

We have not completed validation of the regulatory methods. However, we expect your continued cooperation to resolve any problems that may be identified.

**REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Kati Johnson, Regulatory Project Manager, at (301) 796-1234.

Sincerely,

{See appended electronic signature page}

Eric Colman, MD  
Deputy Director  
Division of Metabolism and Endocrinology Products  
Office of Drug Evaluation II  
Center for Drug Evaluation and Research

Enclosures: Content of Labeling (Package Insert and Patient Information)
Carton and Container Labeling

Sample Labeling:
- Liptruzet 10/10 foil pouch (7 tablets)
- Liptruzet 10/10 blister (7 tablets)
- Liptruzet 10/10 carton (28 tablets)

- Liptruzet 10/20 foil pouch (7 tablets)
- Liptruzet 10/20 blister (7 tablets)
- Liptruzet 10/20 carton (28 tablets)

- Liptruzet 10/40 foil pouch (7 tablets)
- Liptruzet 10/40 blister (7 tablets)
- Liptruzet 10/40 carton (28 tablets)

- Liptruzet 10/80 foil pouch (7 tablets)
- Liptruzet 10/80 blister (7 tablets)
- Liptruzet 10/80 carton (28 count)

Trade Labeling:
- Liptruzet 10/10 foil pouch (10 tablets)
- Liptruzet 10/10 plastic case front
- Liptruzet 10/10 plastic case back
- Liptruzet 10/10 foil lidding
- Liptruzet 10/10 carton (30 tablets)
- Liptruzet 10/10 carton (90 tablets)

- Liptruzet 10/20 foil pouch (10 tablets)
- Liptruzet 10/20 plastic case front
- Liptruzet 10/20 plastic case back
- Liptruzet 10/20 foil lidding
- Liptruzet 10/20 carton (30 tablets)
- Liptruzet 10/20 carton (90 tablets)

- Liptruzet 10/40 foil pouch (10 tablets)
- Liptruzet 10/40 plastic case front
- Liptruzet 10/40 plastic case back
- Liptruzet 10/40 foil lidding
- Liptruzet 10/40 carton (30 tablets)
- Liptruzet 10/40 carton (90 tablets)

- Liptruzet 10/80 foil pouch (10 tablets)
- Liptruzet 10/80 plastic case front
- Liptruzet 10/80 plastic case back
- Liptruzet 10/80 foil lidding
- Liptruzet 10/80 carton (30 tablets)
- Liptruzet 10/80 carton (90 tablets)
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

ERIC C COLMAN
05/03/2013